AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

Rhea-AI Summary

AzurRx BioPharma (NASDAQ: AZRX) is participating in the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO James Sapirstein will engage in one-on-one virtual meetings with investors and pharmaceutical companies, discussing the company's business and clinical development plans. AzurRx specializes in non-systemic therapies for gastrointestinal diseases, with ongoing Phase 2 trials for its lead asset, MS1819, and two other therapies targeting immune-related colitis and COVID-19 gastrointestinal infections.

DELRAY BEACH, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will be participating in the virtual H.C. Wainwright BioConnect 2021 Conference.

James Sapirstein, President & CEO of AzurRx BioPharma, will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Mr. Sapirstein will be available to provide an overview of the Company’s business and clinical development programs and discuss anticipated 2021 milestones.

Details of the event are as follows:

Event:		H.C. Wainwright BioConnect 2021 Conference
Date:		January 11-14, 2021
Registration:		hcwevents.com/bioconnect

About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets: MS1819 – a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis – with two ongoing Phase 2 clinical trials; and two clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for the treatment of grade 1 Immune Checkpoint Inhibitor Associated Colitis (ICI-AC) and diarrhea in oncology patients and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. Additional information on the Company can be found at www.azurrx.com.

For more information:

AzurRx BioPharma, Inc.
1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445
Phone: (646) 699-7855
info@azurrx.com

Investor Relations contact:

LifeSci Advisors, LLC. 
Hans Vitzthum, Managing Director 
1 International Place, Suite 1480 
Boston, MA 02110 
Phone: (617) 430-7578 
hans@lifesciadvisors.com

FAQ

What is the date of the H.C. Wainwright BioConnect 2021 Conference for AzurRx?

The H.C. Wainwright BioConnect 2021 Conference will take place from January 11-14, 2021.

Who from AzurRx will participate in the conference?

James Sapirstein, President & CEO of AzurRx BioPharma, will participate in the conference.

What is AzurRx BioPharma's focus area?

AzurRx BioPharma focuses on developing targeted, non-systemic therapies for gastrointestinal diseases.

What are the ongoing clinical trials related to AzurRx?

AzurRx has two ongoing Phase 2 clinical trials for its recombinant lipase biologic, MS1819.

What types of therapies is AzurRx developing?

AzurRx is developing therapies for exocrine pancreatic insufficiency, immune checkpoint inhibitor-associated colitis, and COVID-19 gastrointestinal infections.